Cynata only have to prove our MSCs are functionally equivalent to other ones and that we can actually scale as we claim.
The ideal position is they design and prove up the treatments, and Cynata industrialises them for scale.
Having Celularity say that is a massive endorsement of CYP and its technology.
Ann: Cyanta & Celularity Inc Execute MOU, page-9
-
- There are more pages in this discussion • 50 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $44.90M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 27654 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 4500 | 1 |
View Market Depth
| Last trade - 16.12pm 16/07/2024 (20 minute delay) ? |
| CYP (ASX) Chart |
Day chart unavailable